About Tessera Therapeutics
Tessera Therapeutics is a company based in Cambridge (United States) founded in 2017 by Robert Citorik.. Tessera Therapeutics has raised $610 million across 3 funding rounds from investors including T. Rowe Price, Flagship Pioneering and Temasek. The company has 149 employees as of December 31, 2021. Tessera Therapeutics operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others.
- Headquarter Cambridge, United States
- Employees 149 as on 31 Dec, 2021
- Founders Robert Citorik
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Tessera Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$610 M (USD)
in 3 rounds
-
Latest Funding Round
$300 M (USD), Series C
Apr 19, 2022
-
Investors
T. Rowe Price
& 16 more
-
Employee Count
149
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Tessera Therapeutics
Tessera Therapeutics has successfully raised a total of $610M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $300 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $300.0M
-
First Round
First Round
(20 Dec 2017)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2022 | Amount | Series C - Tessera Therapeutics | Valuation | ADIA , Artis Ventures | |
| Jan, 2021 | Amount | Series B - Tessera Therapeutics | Valuation | Altitude Life Science Ventures , Alaska Permanent Fund | |
| Dec, 2017 | Amount | Series B - Tessera Therapeutics | Valuation | Temasek |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Tessera Therapeutics
Tessera Therapeutics has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include T. Rowe Price, Flagship Pioneering and Temasek. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage life sciences sectors focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Early-stage startups are invested in by Artis Ventures.
|
Founded Year | Domain | Location | |
|
Life sciences-focused venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Tessera Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Tessera Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tessera Therapeutics Comparisons
Competitors of Tessera Therapeutics
Tessera Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Metagenomi and Prime Medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| domain | founded_year | HQ Location |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
|
| domain | founded_year | HQ Location |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| domain | founded_year | HQ Location |
Genetic therapies for diseases are developed using prime editing technology.
|
|
| domain | founded_year | HQ Location |
A CRISPR-based gene-editing platform is developed for therapeutic applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tessera Therapeutics
Frequently Asked Questions about Tessera Therapeutics
When was Tessera Therapeutics founded?
Tessera Therapeutics was founded in 2017.
Where is Tessera Therapeutics located?
Tessera Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Tessera Therapeutics?
Michael Severino is the current CEO of Tessera Therapeutics.
Is Tessera Therapeutics a funded company?
Tessera Therapeutics is a funded company, having raised a total of $610M across 3 funding rounds to date. The company's 1st funding round was a Series B of $80M, raised on Dec 20, 2017.
How many employees does Tessera Therapeutics have?
As of Dec 31, 2021, the latest employee count at Tessera Therapeutics is 149.
What does Tessera Therapeutics do?
Tessera Therapeutics was founded in 2017 in Cambridge, United States, within the biotechnology sector. Genome engineering solutions are developed to address diseases at their genetic source. RNA-based gene writing is utilized to modify base pairs, perform small insertions or deletions, and integrate full genes into the genome. Operations center on advancing therapeutic applications for various conditions.
Who are the top competitors of Tessera Therapeutics?
Tessera Therapeutics's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Who are Tessera Therapeutics's investors?
Tessera Therapeutics has 17 investors. Key investors include T. Rowe Price, Flagship Pioneering, Temasek, SoftBank Vision Fund, and Abu Dhabi Investment Authority.